These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 15912915)
1. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors. Naslafkih A; Sestier F J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915 [TBL] [Abstract][Full Text] [Related]
2. [Statins in primary prevention of coronary heart disease]. Paulweber B Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004 [TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
4. Protecting the heart: a practical review of the statin studies. Ong HT MedGenMed; 2002 Dec; 4(4):1. PubMed ID: 12817199 [TBL] [Abstract][Full Text] [Related]
6. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Yokoyama M; Origasa H; Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313 [TBL] [Abstract][Full Text] [Related]
7. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Martens LL; Guibert R Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684 [TBL] [Abstract][Full Text] [Related]
10. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486 [TBL] [Abstract][Full Text] [Related]
12. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. Tachibana E; Watanabe I; Nagao K; Kanmatsuse K J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271 [TBL] [Abstract][Full Text] [Related]
13. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Bays HE; Davidson M; Jones MR; Abby SL Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026 [TBL] [Abstract][Full Text] [Related]
14. Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease. Verri V; Cunha AB; Tessarolo LE; Carneiro RC; RomĂȘo Filho LJ Rev Port Cardiol; 2004 Sep; 23(9):1089-105. PubMed ID: 15587571 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Sharma R; Mahajan M; Singh B; Bal BS; Kant R J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006 [TBL] [Abstract][Full Text] [Related]
16. Prevention of coronary heart disease through cholesterol reduction. Grundy SM Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652 [TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066 [TBL] [Abstract][Full Text] [Related]
18. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304 [TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175 [TBL] [Abstract][Full Text] [Related]
20. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]